Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 EUR | +0.50% | +1.26% | +6.63% |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 27.61 | 23.62 | 28.49 | 30.5 | - | - |
Enterprise Value (EV) 1 | 27.61 | 23.62 | 28.49 | 22.1 | 20.5 | 30.5 |
P/E ratio | -18.4 x | 39.3 x | 15.7 x | 15.5 x | 15.5 x | 13.4 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 2.17 x | 1.99 x | 1.75 x | 1.55 x |
EV / Revenue | - | - | 2.17 x | 1.44 x | 1.18 x | 1.55 x |
EV / EBITDA | - | - | 12.9 x | 9.61 x | 7.32 x | 8.97 x |
EV / FCF | - | - | - | 6.14 x | 12.8 x | 17.9 x |
FCF Yield | - | - | - | 16.3% | 7.81% | 5.57% |
Price to Book | - | - | - | 2.64 x | 2.26 x | - |
Nbr of stocks (in thousands) | 15,046 | 15,046 | 15,114 | 15,174 | - | - |
Reference price 2 | 1.835 | 1.570 | 1.885 | 2.010 | 2.010 | 2.010 |
Announcement Date | 2/16/22 | 2/15/23 | 2/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | 13.1 | 15.3 | 17.4 | 19.7 |
EBITDA 1 | - | - | 2.2 | 2.3 | 2.8 | 3.4 |
EBIT 1 | - | - | 1.8 | 1.9 | 2.5 | 2.8 |
Operating Margin | - | - | 13.74% | 12.42% | 14.37% | 14.21% |
Earnings before Tax (EBT) 1 | - | - | 2.2 | 2.1 | 2.5 | 2.8 |
Net income 1 | -1.5 | 0.6 | 1.9 | 1.9 | 2 | 2.3 |
Net margin | - | - | 14.5% | 12.42% | 11.49% | 11.68% |
EPS 2 | -0.1000 | 0.0400 | 0.1200 | 0.1300 | 0.1300 | 0.1500 |
Free Cash Flow 1 | - | - | - | 3.6 | 1.6 | 1.7 |
FCF margin | - | - | - | 23.53% | 9.2% | 8.63% |
FCF Conversion (EBITDA) | - | - | - | 156.52% | 57.14% | 50% |
FCF Conversion (Net income) | - | - | - | 189.47% | 80% | 73.91% |
Dividend per Share 2 | - | - | - | - | - | - |
Announcement Date | 2/16/22 | 2/15/23 | 2/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|
Net sales 1 | 6.5 | 6.6 | 7.6 | 7.7 | 8.6 | 8.8 |
EBITDA 1 | 1.7 | 0.5 | 1.2 | 1.1 | 1.3 | 1.2 |
EBIT 1 | 1.5 | 0.3 | 1 | 0.9 | 1.3 | 1.2 |
Operating Margin | 23.08% | 4.55% | 13.16% | 11.69% | 15.12% | 13.64% |
Earnings before Tax (EBT) 1 | 1.7 | 0.5 | 1.1 | 1 | 1.3 | 1.2 |
Net income 1 | 1.4 | 0.5 | 1 | 0.9 | 1.3 | 1.2 |
Net margin | 21.54% | 7.58% | 13.16% | 11.69% | 15.12% | 13.64% |
EPS 2 | 0.0900 | 0.0300 | 0.0600 | 0.0600 | 0.0900 | 0.0800 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 8/9/23 | 2/14/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 8.4 | 10 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | 3.6 | 1.6 | 1.7 |
ROE (net income / shareholders' equity) | - | - | - | 18.2% | 15.8% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | 0.7600 | 0.8900 | - |
Cash Flow per Share 2 | - | - | - | 0.2900 | 0.1600 | - |
Capex 1 | - | - | - | 0.7 | 0.7 | 0.8 |
Capex / Sales | - | - | - | 4.58% | 4.02% | 4.06% |
Announcement Date | 2/16/22 | 2/15/23 | 2/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.63% | 32.86M | |
+10.25% | 8.29B | |
-3.44% | 4.68B | |
+5.11% | 2.15B | |
-21.73% | 1.2B | |
-3.15% | 898M | |
-8.36% | 807M | |
-19.75% | 791M | |
-21.82% | 698M | |
-56.02% | 698M |
- Stock Market
- Equities
- BIOBV Stock
- Financials Biohit Oyj